Calcium Channel Blocker Market Report 2025

The calcium channel blocker market size has grown strongly in recent years. It will grow from $15.56 billion in 2024 to $16.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increased incidence of cardiovascular diseases, aging population, advancements in medical research, changing lifestyles, increased awareness.

The calcium channel blocker market size is expected to see strong growth in the next few years. It will grow to $22.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising global burden of cardiovascular diseases, personalized medicine trends, increased access to healthcare, expansion of indications, regulatory approvals and market expansions. Major trends in the forecast period include market growth, technological advancements, regulatory landscape, competitive analysis, patient preferences and awareness.

The growth of the calcium channel blocker market is anticipated to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases, affecting the heart or blood vessels, have become more prevalent, leading to a heightened demand for interventions such as calcium channel blockers (CCBs). These medications are employed to reduce the risk of heart failure and stroke. An August 2022 report from the American College of Cardiology predicts a rise in cardiovascular risk factors in the United States between 2025 and 2060. Notably, diabetes is projected to increase by 39.3%, dyslipidemia by 27.6%, hypertension by 25.1%, and obesity by 18.3%. Substantial increases are also expected in cardiovascular disease rates, including stroke, heart failure, ischemic heart disease, and heart attack. This surge in cardiovascular conditions is driving the growth of the calcium channel blocker market.

The growing healthcare expenditure is anticipated to propel the calcium channel blocker market in the future. Healthcare expenditure encompasses the total resources, including financial allocations, dedicated to healthcare services and related activities over a specific period, typically measured annually. Increased healthcare spending creates a conducive environment for the calcium channel blocker market by improving access, affordability, research and development, and overall patient care, thereby contributing to a robust healthcare system for effectively managing cardiovascular conditions. For example, in July 2024, the American Medical Association, a professional organization in the U.S., reported that health expenditures rose by 4.1% in 2022, reaching a total of $4.5 trillion, which translates to $13,493 per person. Hence, the rise in healthcare expenditure is driving the growth of the calcium channel blocker market.

Product innovation emerges as a key trend in the calcium channel blocker market, with major companies emphasizing the development of innovative products to maintain their market position. For example, in June 2022, CMP Pharma, a US-based pharmaceutical manufacturing company, introduced Norliqva, the first and only oral liquid solution of the besylate salt of amlodipine - an extended-release calcium channel blocker. Norliqva addresses the challenges associated with crushing or synthesizing amlodipine tablets, ensuring uniform dosing and bioequivalence. This innovative product caters to patients who require amlodipine but face difficulties with swallowing or are unable to swallow. The focus on product innovation is a testament to the dynamic nature of the calcium channel blocker market and the commitment of major companies to meeting evolving healthcare needs.

Major companies within the calcium channel blocker market are strategically developing innovative products, specifically tablets tailored for the treatment of Pulmonary Arterial Hypertension (PAH). These tablets serve as oral pharmaceutical formulations designed to address the unique medical condition of PAH. In May 2022, Zydus, an India-based pharmaceutical company, achieved approval from the US Food and Drug Administration (FDA) for Selexipag tablets. Selexipag is indicated for use in adults to manage Pulmonary Arterial Hypertension, with the goal of delaying disease progression and reducing the likelihood of hospitalization associated with PAH. As a prostacyclin receptor agonist, this medication contributes to the comprehensive management of PAH.

In November 2023, LXO Group, a France-based pharmaceutical company specializing in non-generic prescription medicines, acquired Nimotop from Bayer for an undisclosed amount. This acquisition is part of LXO Group's strategy to increase its market presence, enhance its product offerings, and foster innovation within the industry. Bayer AG, a Germany-based pharmaceutical and life sciences company, is known for developing calcium channel blockers (CCBs).

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calcium channel blocker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Calcium channel blockers are medications designed to inhibit calcium from entering the muscle cells in the heart and blood vessels. They are commonly used in the treatment of various conditions such as high blood pressure, angina (chest pain), and irregular heart rhythms.

These drugs belong to different classes including dihydropyridine, benzothiazepine, phenylalkylamine, and others. Dihydropyridines specifically function by blocking calcium channels present in the muscle cells of the heart and arterial blood vessels, thereby reducing the influx of calcium ions into these cells. These medications are indicated for conditions such as hypertension (high blood pressure), chest pain, and certain types of arrhythmias. They are typically administered orally, through parenteral routes, or by other methods, and are utilized by hospitals, homecare settings, specialty clinics, and other end-users for medical purposes.

The calcium channel blocker market research report is one of a series of new reports that provides calcium channel blocker market statistics, including calcium channel blocker industry global market size, regional shares, competitors with calcium channel blocker market share, detailed calcium channel blocker market segments, market trends, and opportunities, and any further data you may need to thrive in the calcium channel blocker industry. This calcium channel blocker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The calcium channel blocker market consists of sales of amlodipine, nicardipine, isradipine, diltiazem, and verapamil drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.